人才隊(duì)伍
返回列表
何玉先
主要研究方向：
艾滋病的分子病毒學(xué)和免疫學(xué)、基因治療及抗病毒藥物
主持承擔(dān)主要科研項(xiàng)目：
1、國(guó)家自然科學(xué)基金重點(diǎn)項(xiàng)目“HIV膜融合機(jī)制及強(qiáng)效抑制劑作用機(jī)制的系統(tǒng)研究”（82230076）
2、國(guó)家自然科學(xué)基金重點(diǎn)項(xiàng)目“HIV感染膜融合的動(dòng)力學(xué)及分子機(jī)制研究”（81630061）
3、國(guó)家自然科學(xué)基金面上項(xiàng)目“新型HIV膜融合抑制劑的作用機(jī)制和優(yōu)化”（81473255）
4、國(guó)家自然科學(xué)基金面上項(xiàng)目 “HIV融合蛋白M-T鉤子的結(jié)構(gòu)與功能”（81271830）
5、國(guó)家自然科學(xué)基金面上項(xiàng)目 “HIV-1融合蛋白核心結(jié)構(gòu)鑒定及新型抑制劑設(shè)計(jì)”（30870123）
6、國(guó)家杰出青年基金項(xiàng)目“醫(yī)學(xué)病毒學(xué)”（81025009）
7、十三五國(guó)家科技重大專(zhuān)項(xiàng)“基于強(qiáng)效HIV進(jìn)入抑制劑的暴露前預(yù)防策略研究”(2018ZX10301103)
8.十二五國(guó)家科技重大專(zhuān)項(xiàng)“基于廣譜中和抗體的艾滋病功能性治愈方法究”(2014ZX10001001-001)
9.十一五國(guó)家科技重大專(zhuān)項(xiàng)“病原體宿主細(xì)胞相互作用藥物靶標(biāo)研究”（2009ZX10004-303）
10.國(guó)家重點(diǎn)研發(fā)計(jì)劃“I型包膜病毒侵入機(jī)制”（2010CB530102）
近年代表性論文：
1、Yanni Gong, Yuxian He. Cell membrane anchoring strategies for HIV gene therapy. Cell Mol Immunol, 2023,20(6):683-685
2、Jing Xue, Huihui Chong, Yuanmei Zhu, Jingjing Zhang, Ling Tong, Jiahan Lu, Ting Chen, Zhe Cong, Qiang Wei, Yuxian He. Efficient treatment and pre-exposure prophylaxis in rhesus macaques by an HIV fusion-inhibitory lipopeptide. Cell, 2022, 185(1): 131-144
3、Yue Chen, Hongliang Jin, Xiaoran Tang, Li Li, Xiuzhu Geng, Yuanmei Zhu, Huihui Chong, Yuxian He. Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targ eting the gp41 fusion protein: new strategies for HIV gene therapy. Emerg Microbes Infect, 2022, 11(1): 30-49
4、Hongliang Jin, Xiaoran Tang, Li Li, Yue Chen, Yuanmei Zhu, Huihui Chong, Yuxian He. Generation of HIV-resistant cells with a single-domain antibody: implications for HIV-1 gene therapy. Cell Mol Immunol, 2021, 18(3): 660-674
5、Yuanmei Zhu, Danwei Yu, Yue Hu, Tong Wu, Huihui Chong, Yuxian He. SARS-CoV-2 derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses. Signal Transduct Targeted Ther, 2021; 6:294
6、Danwei Yu, Yuanmei Zhu, Yan H, Tong Wu, Huihui Chong, Yuxian He. Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus. Emerg Microbes Infect. 2021; 10(1):810-821
7、Yuanmei Zhu, Danwei Yu, Yang Han, Hongxia Yan, Huihui Chong, Lili Ren, Jianwei Wang, Taisheng Li, Yuxian He. Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recover ed SARS patients and immunized animals. Sci Adv, 2020, 6(45): eabc9999
8、Danwei Yu,Jing Xue, Huamian Wei, Zhe Cong, Ting Chen, Yumei Zhu, Huihui Chong, Qiang Wei, Chuan Qin,Yuxian He. Therapeutic efficacy and resistance selection of a lipopeptide fusion inhibitor in simian immunodeficiency virus -infected rhesus macaques. J Virol. 2020;94(15): e00384-20
9、Yuanmei Zhu, Xiaohui Ding, Danwei Yu, Huihui Chong, Yuxian He. The Tryptophan-Rich Motif of HIV-1 Gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of Gp41 and Its Inhibitors. J Virol. 2020; 94(1): e01358-19
10、Huihui Chong, Jing Xue, Yuanmei Zhu, Zhe Cong, Ting Chen, Qiang Wei, Chuan Qin, Yuxian He. Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppress ion in rhesus macaques. PLoS Pathog, 2019, 15(2): e1007552
成果轉(zhuǎn)化及臨床試驗(yàn)
1、國(guó)家1類(lèi)抗HIV新藥“利普韋肽”進(jìn)入II期臨床試驗(yàn)
2、國(guó)家1類(lèi)抗HIV新藥“注射用LP-98”進(jìn)入I期臨床試驗(yàn)
3、國(guó)家1類(lèi)抗SARS-CoV-2新藥YKYY017進(jìn)入II/III期臨床試驗(yàn)
4、廣譜抗病毒藥物IPBZS01實(shí)現(xiàn)成果轉(zhuǎn)化并開(kāi)展Pre-IND研究